|Day Low/High||20.62 / 21.51|
|52 Wk Low/High||12.56 / 88.54|
Oppenheimer analysts say Endo's (ENDP) recent management shake-up indicates the company is re-focusing on its generics business, rather than M&As.
It appears Twitter will need more than takeover chatter to stay aloft, Oppenheimer analysts say.
The promotion of Paul Campanelli to CEO indicates a change in the company's focus from acquiring other firms to its roots as a generic pharmaceutical firm.
Here's a technical look at how to trade some of the most active stocks on the market.
Endo (ENDP) stock was trading sharply higher Friday morning after naming Paul Campanelli CEO.
The pharmaceutical company is reportedly up for sale after being dogged by Starboard Value for months, and could go for up to $41 million.
Endo (ENDP) stock was falling Friday afternoon after Hillary Clinton released a plan to combat skyrocketing drug prices.
Cutting down the 7 best S&P 500 stocks in August to a field of 2.
These stocks show technical characteristics of changing course.
Endo (ENDP) stock was higher in mid-afternoon trading after Mizuho upgraded shares to 'buy' after the company's second-quarter earnings.
Shares of the specialty-healthcare firm climbed on better-than-expected profits for the second quarter.
Norwegian Cruise Line was pulling down industry-peer Royal Caribbean Tuesday on lowered guidance.
Endo (ENDP) reported better-than-expected earnings and revenue for the 2016 second quarter and named a new manager.
Trade-Ideas LLC identified Endo International (ENDP) as a post-market leader candidate
The generic-drug industry has undergone a flurry of acquisition activity over the past 18 months, highlighted by the long-anticipated but only recent closing of Teva Pharmaceutical's purchase of Allergan's generics.
Trade-Ideas LLC identified Endo International (ENDP) as a strong on high relative volume candidate
Listen to what the companies are actually telling you. Then assess what that might mean for the future, Cramer says.
Endo Pharmaceuticals is most under pressure, analysts say.
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Endo International plc ("Endo" or the "Company") (NASDAQ:ENDP) ...